Brain tumors known as gliomas remain one of the greatest challenges in cancer treatment. The research, published in Nature Cancer, suggests an experimental vaccine could improve long-term survival for patients whose tumors carry a common genetic mutation. By teaching immune cells to recognise this altered protein, researchers hope they can destroy cancer cells while sparing healthy brain tissue. T cells travelled into the tumors and attacked cancer cells directly, while B cells produced antibodies that recognised the mutated protein. The trial was designed primarily to evaluate safety, and it did not include a control group receiving standard treatment alone.